1. Key Insights

2. Report Introduction

3. Chronic Hepatitis B Market Overview at a Glance

3.1. Market Share (%) Distribution of Chronic Hepatitis B in 2019

3.2. Market Share (%) Distribution of Chronic Hepatitis B in 2032

4. Executive Summary of Chronic Hepatitis B

4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Acute and Chronic Hepatitis B Infection

6.3. Signs and Symptoms

6.4. Risk Factors and Causes

6.5. Transmission of Hepatitis B Virus

6.6. Pathophysiology

6.7. Stages of HBV Infection

6.8. Complications of Hepatitis B Virus Infection

7. Diagnosis of Hepatitis B Infection

7.1. Screening Tests for Hepatitis B Infection

7.2. Liver Related Blood Tests

7.3. Tests to Diagnose Hepatitis B Virus

7.3.1. Medical History and Physical Exam

7.3.2. Imaging Tests

7.3.3. MRI and CT Scans

7.4. Liver Biopsy for Hepatitis B Virus

7.5. Diagnostic Guidelines of Hepatitis B Infection

7.5.1. World Health Organization (WHO) Diagnostic Guidelines, 2015

7.5.2. American Association for the Study of Liver Diseases (AASLD) Diagnostic Guidelines, 2018

7.5.3. European Association for the Study of the Liver (EASL) Diagnostic Guidelines, 2017

7.6. Prevention of Hepatitis B Infection

8. Current Treatment Practices

8.1. Treatment Algorithm

8.2. Treatment Guidelines

8.2.1. AASLD 2018 Practice Guidelines for Treatment of Chronic Hepatitis

8.2.2. European Association for the Study of the Liver (EASL) 2017 Clinical Practice Guidelines for Hepatitis

8.2.3. Hepatitis B management: Guidance for the primary care provider

8.2.4. World Health Organization Guidelines for the management and treatment of Chronic Hepatitis B

8.2.5. Guidelines for Treatment of Chronic Hepatitis B by the Chinese Society of Infectious Diseases and the Chinese Society of Hepatology, 2019

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. Assumptions and Rationale: The 7MM and China

9.3. Epidemiology Scenario in the 7MM and China

9.3.1. Prevalent cases of Chronic Hepatitis B in the 7MM and China

9.4. Epidemiology Scenario in the US

9.4.1. Prevalent cases of Chronic Hepatitis B in the US

9.4.2. Diagnosed prevalent cases of Chronic Hepatitis B in the US

9.4.3. Gender-specific diagnosed prevalent cases of Chronic Hepatitis B in the US

9.4.4. Age-specific diagnosed prevalent cases of Chronic Hepatitis B in the US

9.4.5. Type-specific diagnosed prevalent cases of Chronic Hepatitis B in the US

9.4.6. Total treated cases of Chronic Hepatitis B in the US

9.5. Epidemiology Scenario in EU4 and the UK

9.5.1. Prevalent cases of Chronic Hepatitis B in EU4 and the UK

9.5.2. Diagnosed prevalent cases of Chronic Hepatitis B in EU4 and the UK

9.5.3. Gender-specific diagnosed prevalent cases of Chronic Hepatitis B in EU4 and the UK

9.5.4. Age-specific diagnosed prevalent cases of Chronic Hepatitis B in EU4 and the UK

9.5.5. Type-specific diagnosed prevalent cases of Chronic Hepatitis B in EU4 and the UK

9.5.6. Total treated cases of Chronic Hepatitis B in EU4 and the UK

9.6. Epidemiology Scenario in Japan

9.6.1. Prevalent Cases of Chronic Hepatitis B in Japan

9.6.2. Diagnosed prevalent cases of Chronic Hepatitis B in Japan

9.6.3. Gender-specific diagnosed prevalent cases of Chronic Hepatitis B in Japan

9.6.4. Age-specific diagnosed prevalent cases of Chronic Hepatitis B in Japan

9.6.5. Type-specific diagnosed prevalent cases of Chronic Hepatitis B in Japan

9.6.6. Total treated cases of Chronic Hepatitis B in Japan

9.7. Epidemiology Scenario in China

9.7.1. Prevalent Cases of Chronic Hepatitis B in China

9.7.2. Diagnosed prevalent cases of Chronic Hepatitis B in China

9.7.3. Gender-specific diagnosed prevalent cases of Chronic Hepatitis B in China

9.7.4. Age-specific diagnosed prevalent cases of Chronic Hepatitis B in China

9.7.5. Type-specific diagnosed prevalent cases of Chronic Hepatitis B in China

9.7.6. Total treated cases of Chronic Hepatitis B in China

10. Patient Journey

11. Key Endpoints in Chronic Hepatitis B Clinical Trials

12. Marketed Therapies

12.1. Key Cross of Marketed Therapies

12.2. VEMLIDY (tenofovir alafenamide): Gilead Sciences

12.2.1. Product description

12.2.2. Regulatory milestones

12.2.3. Other developmental activities

12.2.4. Pivotal clinical trial

12.2.5. Ongoing pipeline activity

13. Emerging Therapies

13.1. Key cross competition - Emerging Therapies

13.2. GSK3228836 (bepirovirsen): GlaxoSmithKline/Ionis Pharma

13.2.1. Product description

13.2.2. Other developmental activities

13.2.3. Clinical developmental activities

13.2.4. Safety and efficacy

13.3. Hydronidone (F-351): Beijing Continent Pharmaceutical

13.3.1. Product description

13.3.2. Other developmental activities

13.3.3. Clinical developmental activities

13.3.4. Safety and efficacy

13.4. Bepirovirsen (GSK3228836) followed by GSK3528869A: GlaxoSmithKline

13.4.1. Product description

13.4.2. Clinical developmental activities

13.5. ASC22 (envafolimab): Ascletis Pharmaceuticals

13.5.1. Product description

13.5.2. Other developmental activities

13.5.3. Clinical developmental activities

13.5.4. Safety and efficacy

13.6. VIR-2218 and VIR-3434: Vir Biotechnology

13.6.1. Product description

13.6.2. Other developmental activities

13.6.3. Clinical developmental activities

13.6.4. Safety and efficacy

13.7. BRII-835 (VIR-2218) and BRII-179 (VBI-2601): Brii Biosciences and Vir Biotechnology

13.7.1. Product description

13.7.2. Other developmental activities

13.7.3. Clinical developmental activities

13.7.4. Safety and efficacy

13.8. JNJ-73763989 (JNJ-3989) and JNJ-56136379 (JNJ-6379): Janssen and Arrowhead Pharmaceuticals

13.8.1. Product description

13.8.2. Other developmental activities

13.8.3. Clinical developmental activities

13.8.4. Safety and efficacy

14. Discontinued Drugs

14.1. Key Cross of Discontinued Drugs

14.2. Vebicorvir (VBR/ABI-H0731): Assembly Biosciences

14.2.1. Product description

14.2.2. Other developmental activities

14.2.3. Clinical developmental activities

14.2.4. Safety and efficacy

14.3. Bersacapavir (JNJ-56136379/JNJ-6379): Janssen Sciences Ireland

14.3.1. Product description

14.3.2. Clinical developmental activities

14.3.3. Safety and efficacy

14.4. Vesatolimod (formerly GS-9620): Gilead Sciences

14.4.1. Product description

14.4.2. Clinical developmental activities

14.4.3. Safety and efficacy

14.5. GS-4774: Gilead Sciences

14.5.1. Product description

14.5.2. Other developmental activities

14.5.3. Clinical developmental activities

14.5.4. Safety and efficacy

14.6. ALG-020572: Aligos Therapeutics

14.6.1. Product description

14.6.2. Clinical developmental activities

14.7. ALG-010133: Aligos Therapeutics

14.7.1. Product description

14.7.2. Clinical developmental activities

14.8. AB-506: Arbutus Biopharma

14.8.1. Product description

14.8.2. Safety and efficacy

15. Chronic Hepatitis B: The 7MM and China Analysis

15.1. Key Findings

15.2. Market Outlook

15.3. Attribute Analysis

15.4. Key Market Forecast Assumptions

15.5. The 7MM and China Market Size

15.5.1. Total market size of Chronic Hepatitis B in the 7MM and China

15.6. The United States Market Size

15.6.1. Total market size of Chronic Hepatitis B in the US

15.6.2. Market size of Chronic Hepatitis B by therapies in the US

15.7. EU4 and the UK Market Size

15.7.1. Total market size of Chronic Hepatitis B in EU4 and the UK

15.7.2. The market size of Chronic Hepatitis B by therapies in EU4 and the UK

15.8. Japan Market Size

15.8.1. Total market size of Chronic Hepatitis B in Japan

15.8.2. Market size of Chronic Hepatitis B by therapies in Japan

15.9. China Market Size

15.9.1. Total market size of Chronic Hepatitis B in China

15.9.2. Market size of Chronic Hepatitis B by therapies in China

16. Market Access and Reimbursement

16.1. Key HTA decisions for Chronic Hepatitis B

16.2. Patient access programs

17. KOL Views

18. SWOT Analysis

19. Unmet Needs

20. Appendix

20.1. Bibliography

20.2. Acronyms and Abbreviations

20.3. Report Methodology

21. DRA Capabilities

22. Disclaimer

23. About DRA